Texas carried out the lethal‑injection execution of Jamaal Howard on Oct. 8, 2026, despite his attorneys’ objections that the same drug used in a recent Tennessee execution could pose a risk.
The case revives long‑standing faith‑based concerns about the humanity of capital punishment and the moral responsibility of the state to ensure a painless death. Christians who value the sanctity of life view the possibility of a botched injection as an additional tragedy that conflicts with the call to treat every person with dignity, even in judgment.
Howard, 46, was pronounced dead at 8:03 p.m. after the pentobarbital began taking effect. Witnesses reported that he took a few breaths, gasped, produced snoring sounds, coughed, and then the noises grew quieter. His movements stopped entirely after about thirty seconds, and he was officially declared dead nineteen minutes later.
His lawyers highlighted the failed execution of Tennessee inmate Christa Pike, who survived two doses of the same drug on Sept. 30. Pike’s experience, the first modern‑era survival of a lethal injection, raised alarms that a similar protocol could lead to unnecessary suffering.
The U.S. Supreme Court denied Howard’s emergency appeal without explanation, with Justice Ketanji Brown Jackson issuing the sole public dissent. Earlier, the Texas Court of Criminal Appeals had rejected two separate requests to halt the execution on drug‑safety grounds.
Howard was convicted of capital murder for the 2000 robbery of a convenience store in Silsbee, Texas, where he shot 42‑year‑old clerk Vickie Swartout and stole $114. At the time of the crime he was 20 years old. His attorneys also argued that he was intellectually disabled, a claim the state said lacked sufficient evidence.
The execution occurred amid several capital punishments carried out in Texas during 2026, prompting renewed scrutiny of lethal‑injection protocols and calls for greater transparency.
On the same day, a Tennessee judge ordered preservation of evidence related to Pike’s botched execution, indicating that legal challenges over the drug’s use may continue in multiple states.